Clinical trial for the treatment of autoimmune cytopenias by using rituximab

Clinical trial for the treatment of autoimmune cytopenias by using rituximab - Clinical trial for the treatment of autoimmune cytopenias by using rituximab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021446

Enrollment

Registered

2016-03-11

Start date

2011-06-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune cytopenias

Interventions

The administration of rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Neutrophil counts less than 1000/uL Hb less than 10 g/dL Pletalets counts less than 20000/uL

Exclusion criteria

Exclusion criteria: The patients who do not agree to this study. The patients with a history of serious sensitivity to product derived from an ingredient of this medicine or mouse protein. The patients of the hepatitis B virus carrier The patients who are judged to be inadequate for this trial by the judgment of the doctor

Design outcomes

Primary

Measure	Time frame
Survival period after the rituximab administration	—

Secondary

Measure	Time frame
evaluation of WBC, neutro, RBC and Plts.	—

Countries

Japan

Contacts

Public ContactHideaki Maeba

Kanazawa University Pediatrics

pedialib@med.kanazawa-u.ac.jp076-265-2313

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026